KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) EPS (Basic) (2016 - 2025)

Inovio Pharmaceuticals' EPS (Basic) history spans 16 years, with the latest figure at -$1.0 for Q3 2025.

  • For Q3 2025, EPS (Basic) fell 12.36% year-over-year to -$1.0; the TTM value through Sep 2025 reached -$2.68, up 39.91%, while the annual FY2024 figure was -$3.95, 35.14% up from the prior year.
  • EPS (Basic) for Q3 2025 was -$1.0 at Inovio Pharmaceuticals, down from -$0.61 in the prior quarter.
  • Across five years, EPS (Basic) topped out at -$0.15 in Q3 2022 and bottomed at -$16.5 in Q4 2021.
  • The 5-year median for EPS (Basic) is -$0.89 (2024), against an average of -$2.3.
  • The largest annual shift saw EPS (Basic) tumbled 14900.0% in 2021 before it soared 91.84% in 2023.
  • A 5-year view of EPS (Basic) shows it stood at -$16.5 in 2021, then increased by 20.55% to -$13.11 in 2022, then soared by 91.84% to -$1.07 in 2023, then skyrocketed by 47.66% to -$0.56 in 2024, then plummeted by 78.57% to -$1.0 in 2025.
  • Per Business Quant, the three most recent readings for INO's EPS (Basic) are -$1.0 (Q3 2025), -$0.61 (Q2 2025), and -$0.51 (Q1 2025).